ProACT Post-Approval Study
Recruiting · Not applicable · NCT03767595
Conditions: Stress Urinary Incontinence
At a glance
- Research payments reported, 2025
- $66,486
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 145
About the trial
- Sponsor
- Uromedica
- Tested
- ProACT Adjustable Continence Therapy for Men (device)
- Dates
- Started 2019-02-19; completion 2031-12-31
- Results posted
- Not yet
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Uromedica, Incorporated reported $66,486 in research payments for this study in 2025 (13 payments).
Products named: Proact
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Brian Flynn, MD Urology · Aurora, CO
- Lindsey M. Hartsell, M.D. Urology · Atlanta, GA
- Bahaa S. Malaeb, M.D. Urology · Ann Arbor, MI
- Andrew P. Windsperger, MD Urology · Sartell, MN
- Henry E. Ruiz, MD Urology · Edinburg, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Colorado Hospital Authority, CO $30,140
- University of Michigan Health System, MI $13,051
- Centracare Urology Clinic $10,490
- Dhr Health Institute $9,200
- Emory University Hospital, GA $3,605
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.